King Pharmaceuticals, Inc. Board Under Investors Investigation

If you are a current investor in King Pharmaceuticals, Inc. (NYSE:KG) shares, and/or have any information relating the investigation, you have certain options and you should contact the Shareholders Foundation.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Company Name(s):

King Pharmaceuticals

Affected Securities:

NYSE: KG

In response to the buyout offer by Pfizer to take over King Pharmaceuticals, Inc. at $14.25 an investigation on behalf of investors of King Pharmaceuticals, Inc. (NYSE:KG) over possible breaches of fiduciary duties in connection with the proposed takeover was announced.

The investigation by a law firm concern whether King Pharmaceuticals and its Board of Directors breached their fiduciary duties owed to King Pharmaceuticals, Inc. (NYSE:KG) investors by agreeing to the current conditions of the proposed takeover by Pfizer.

On Tuesday, October 12, 2010, King Pharmaceuticals, Inc. (NYSE: KG) and Pfizer Inc.(NYSE: PFE) announced that they have entered into a merger agreement under which Pfizer will acquire King Pharmaceuticals, Inc for $3.6 billion in cash, or $14.25 per share. According to King Pharmaceuticals the offer represents a premium of approximately 40% to King Pharmaceuticals’ closing price as of October 11, 2010, and 46% percent to the one-month average closing price as of the same date.

But the investigation by a law firm questions whether the sale process and the offered price are unfair to the shareholders of King Pharmaceuticals, Inc. (NYSE:KG).

Shares of King Pharmaceuticals, Inc. (KG), which traded before the news at roughly $10.20 per share, jumped to $14.15 per share or by almost 40% in response to the takeover announcement. But King Pharmaceuticals shares traded as early as April at $12.14, in March as high as $12.54, and in January over $13 per share leaving King Pharmaceuticals investors with a meager premium. During 2007 KG shares traded as high as $21.46 per share and at least one analyst has set a price target of $15.00 per share for King Pharmaceuticals stock. In addition King Pharmaceuticals reported over the past four years steady 12months revenue ranging from $1.565billion to $2.136billion.

Therefore the investigation concerns whether the King Pharmaceuticals board of directors undertook an adequate and fair sales process to obtain fair consideration for all shareholders of King Pharmaceuticals, Inc. (NYSE:KG) and breached their fiduciary duties to King Pharmaceuticals, Inc. (NYSE:KG) shareholder by failing to adequately shop the Company before entering into the transaction with Pfizer.